HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Erythropoietin ameliorates diabetes-associated cognitive dysfunction in vitro and in vivo.

Abstract
Several studies indicate that erythropoietin (EPO) has remarkable neuroprotective effects in various central nervous system disorders, while little is known about the effects of EPO in diabetes-associated cognitive dysfunction. Therefore, the present study aimed to investigate whether EPO ameliorates diabetes-associated cognitive dysfunction in vivo and in vitro. We investigated the protective effects of EPO on high-glucose (HG)-induced PC12 cell death and oxidative stress. The effects of EPO (300 U/kg administered three times a week for 4 weeks) on diabetes-associated cognitive decline were investigated in diabetic rats. EPO significantly increased cell viability, increased the activity of superoxide dismutase, decreased the production of malondialdehyde and reactive oxygen species, and decreased the apoptosis rate. Additionally, LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, abolished the protective effects of EPO in HG-treated PC12 cells. In diabetic rats, EPO prevented deficits in spatial learning and memory in the Morris water maze test. The results of real-time PCR and Western blotting showed that EPO upregulated EPO receptor, PI3K, and phosphorylated Akt2 relative to unphosphorylated Akt2 (p-Akt2/Akt2) and downregulated glycogen synthase kinase-3β (GSK-3β). These studies demonstrate that EPO is an effective neuroprotective agent in the context of diabetes-associated cognitive dysfunction and show that this effect involves the PI3K/Akt/GSK-3β pathway.
AuthorsMeng Wang, Wenhui Yan, Yuan Liu, Hao Hu, Qiang Sun, Xinlin Chen, Weijin Zang, Lina Chen
JournalScientific reports (Sci Rep) Vol. 7 Issue 1 Pg. 2801 (06 05 2017) ISSN: 2045-2322 [Electronic] England
PMID28584284 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Neuroprotective Agents
  • Reactive Oxygen Species
  • Receptors, Erythropoietin
  • Erythropoietin
  • Phosphatidylinositol 3-Kinases
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • Glucose
Topics
  • Animals
  • Apoptosis (drug effects)
  • Cell Survival (drug effects)
  • Cognitive Dysfunction (drug therapy, etiology, metabolism, psychology)
  • Diabetes Complications
  • Diabetes Mellitus, Experimental
  • Disease Models, Animal
  • Erythropoietin (pharmacology)
  • Glucose (metabolism)
  • Glycogen Synthase Kinase 3 beta (metabolism)
  • Models, Biological
  • Neuroprotective Agents (pharmacology)
  • Oxidative Stress (drug effects)
  • PC12 Cells
  • Phosphatidylinositol 3-Kinases (metabolism)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • Rats
  • Reactive Oxygen Species (metabolism)
  • Receptors, Erythropoietin (metabolism)
  • Signal Transduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: